Summary
PROJECT SUMMARY/ABSTRACT The overall objective of this proposal is to further our understanding of the biology and therapeutic potential of C-type natriuretic peptide in hypertrophic cardiomyopathy (HCM). Cardiac fibrosis a key risk factor for the development adverse outcomes in HCM, however, there is no proven medical therapy for HCM that modifies fibrosis in humans, which represents a critical unmet need. The natriuretic peptides ANP and BNP are increased in HCM. However, there is also a third natriuretic peptide, CNP, and we show that HCM is a state of CNP deficiency. CNP is the most potent
